← Back to headlines
Regenxbio Outlines 2026 Milestones for Duchenne, Wet AMD, and Diabetic Retinopathy, Targeting Pivotal Data Releases
Regenxbio has detailed its strategic objectives for 2026, focusing on key therapeutic areas including Duchenne muscular dystrophy, wet age-related macular degeneration (AMD), and diabetic retinopathy. The company anticipates pivotal data releases within this timeframe, underscoring its commitment to advancing these programs towards potential regulatory submissions.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
